LLY - Lilly(Eli) & Co
751.985
6.390 0.850%
Share volume: 21,943
Last Updated: Wed 22 Jan 2025 03:30:06 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.21%
PREVIOUS CLOSE
CHG
CHG%
$745.60
6.39
0.86%
Fundamental analysis
71%
Profitability
89%
Dept financing
25%
Liquidity
51%
Performance
70%
Performance
5 Days
2.29%
1 Month
-6.77%
3 Months
-18.35%
6 Months
-14.28%
1 Year
17.67%
2 Year
116.93%
Key data
Stock price
$751.98
DAY RANGE
$740.14 - $752.24
52 WEEK RANGE
$624.68 - $972.53
52 WEEK CHANGE
$17.15
DIVIDEND
$1.30
EX-DIVIDEND DATE
08/15/2024
NEXT EARNINGS DATE
N/A
Company detail
CEO: David A. Ricks
Region: US
Website: lilly.com
Employees: 39,000
IPO year: 1972
Issue type: Common Stock
Market: NYSE
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: lilly.com
Employees: 39,000
IPO year: 1972
Issue type: Common Stock
Market: NYSE
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic colorectal cancer, and hepatocellular carcinoma. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic ax
Recent news